2021 American Transplant Congress
T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…2021 American Transplant Congress
Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant
*Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…2021 American Transplant Congress
Impact of High-Risk EBV Discordance Status on Survival Outcomes in Kidney Transplant Recipients: A Multivariable Analysis
*Purpose: High-risk EBV discordance has been linked to Post-Transplant Lymphoproliferative Disorder (PTLD) after kidney transplantation; however, the impact on recipient and graft survival is under-reported.…2021 American Transplant Congress
Gain of Function Mutations in Latent Membrane Protein 1 of Epstein Barr Virus are Associated with Increased Risk of Post-Transplant Lymphoproliferative Disorder
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. Clinical Trials of Organ Transplantation in Children (CTOTC)-06 is a prospective…2020 American Transplant Congress
Epidemiology of EBV Infection and EBV Load Kinetics after Pediatric Living Donor Liver Transplantation
National Center for Child Health and Development, Tokyo, Japan
*Purpose: Epstein-Barr virus (EBV) is a ubiquitous virus that infects more than 90% of adult population worldwide. EBV infection after pediatric liver transplantation (LT) accounts…2020 American Transplant Congress
Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…2020 American Transplant Congress
Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database
1United Network for Organ Sharing (UNOS), Richmond, VA, 2Bristol-Myers Squibb, Princeton, NJ
*Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD…2020 American Transplant Congress
Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study
*Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…2020 American Transplant Congress
Genome-Wide Analysis of Epstein Barr Virus Identifies Variations in the Latency Gene EBNA3C That Are Associated with Post Transplant Lymphoproliferative Disorder
Stanford University Sch of Med, Stanford, CA
*Purpose: Epstein Barr virus (EBV) is a gamma herpes virus that is associated with a variety of human malignancies including EBV+ B cell lymphomas in…2020 American Transplant Congress
Role of CAR-T Cell Therapy in Post Transplant Lymphoproliferative Disorder
Transplant, Washington University in St. Louis, Saint Louis, MO
*Purpose: Chimeric Antigen Receptor (CAR) T cells are a genetically modified autologous immunotherapy that uses a patient’s own T cells modified with a chimeric antigen…
- 1
- 2
- 3
- …
- 9
- Next Page »